Revumenib Shows Promise for Advanced Acute Myeloid Leukemia - NCI
Descrição
In the AUGMENT-101 trial, treatment with revumenib caused complete remission in about one-third of participants, all of whom had many prior treatments. The targeted therapy is part of a new class of drugs known as menin inhibitors.
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant
Clinical Trial Results - Cancer Currents Blog - NCI
Effective Menin inhibitor-based combinations against AML with MLL
Al Giovanniello on LinkedIn: Revumenib Shows Promise for Advanced
Revumenib Shows Promise for Advanced Acute Myeloid Leukemia - NCI
Therapeutic implications of menin inhibition in acute leukemias
Research Areas: Treatment - NCI
Namrata Gautam on LinkedIn: T-cell Transfer Therapy - Immunotherapy
Juan Manuel Pérez Huacuja Urista posted on LinkedIn
National Cancer Institute (NCI) on LinkedIn: A new type of
Next Steps for KRAS Inhibitors Focus on Tackling Resistance
Therapeutic implications of menin inhibition in acute leukemias
de
por adulto (o preço varia de acordo com o tamanho do grupo)
/i.s3.glbimg.com/v1/AUTH_59edd422c0c84a879bd37670ae4f538a/internal_photos/bs/2022/d/D/qfBB33SZC0THmA3rrqKg/d1f01870-6afa-44ba-959d-52732a654a82.jpg)
